Zobrazeno 1 - 3
of 3
pro vyhledávání: '"M. V. Volkonskiy"'
Autor:
A. A. Rumyantsev, A. E. Protasova, M. Yu. Sheremet, A. Yu. Goryainova, M. V. Volkonskiy, A. G. Kedrova, S. V. Kuzmicheva, O. N. Aymamedova, Kh. S. Musaeva, S. M. Soroka, O. V. Romanchuk, V. N. Orlova, N. G. Graft, M. R. Ibragimova, Yu. I. Merzlikina, L. V. Stepura, L. B. Tatulova, A. A. Abasova, A. A. Akopyan, E. V. Arsenyeva, Yu. V. Vasilyeva, A. V. Belonogov, L. V. Krivolapova, A. A. Bobryshev, D. Yu. Vovk, I. A. Luev, N. R. Abidova, R. S. Zhikhorev, T. A. Zhelezkova, T. T. Grigoryan, T. A. Makarkina, V. A. Ekimov, A. V. Zhizhina, E. V. Karabina, O. A. Kuchevskaya, V. M. Filippova, T. A. Linchenko, A. A. Lisaeva, A. N. Fedorova, K. S. Maystrenko, E. V. Markizova, E. V. Kogay, E. P. Krasnorutskaya, M. E. Popova, Yu. Yu. Pchelin, R. A. Ryanzhina, D. B. Sidorov, E. B. Shakhnovich, S. M. Alekseev, M. V. Zinkevich, I. O. Belogortsev, V. A. Chubenko, V. M. Moiseenko, N. Kh. Abduloeva, A. A. Lebedinets, L. V. Strakh, L. K. Semenov, M. B. Bolieva, F. Z. Aydaeva
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 4, Pp 104-113 (2024)
Aim. To assess the efficacy and safety of lenvatinib and pembrolizumab for the treatment of mismatch repair-proficient endometrial cancer (EC) in routine clinical practice in Russia.Materials and methods. This multicenter, retrospective, cohort study
Externí odkaz:
https://doaj.org/article/b505b127d35446839d80501e03b80b14
Autor:
A. S. Tyulyandina, E. A. Ulrikh, L. A. Kolomiets, S. E. Krasilnikov, A. G. Kedrova, A. A. Rumyantsev, G. A. Raskin, A. I. Nesterova, M. V. Volkonskiy, O. N. Churuksaeva, A. Yu. Goryainova, V. V. Zhavoronkova, V. N. Dmitriev, S. T. Nazranova, A. V. Shkradyuk, K. S. Volkova, A. I. Arutyunova, S. N. Kunitskaya, L. V. Stepura, T. G. Zolotoreva, E. B. Shakhnovich, E. V. Ponomareva, M. A. Strokova, A. S. Danilova, E. S. Martynova
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 4, Pp 138-146 (2023)
Deficient DNA mismatch repair (dMMR) is a rare molecular disorder found in 20-30 % of endometrial tumors. Laboratory identification of dMMR/microsatellite instability (MSI) has a high diagnostic value, since these impairments are considered as biomar
Externí odkaz:
https://doaj.org/article/dd56d4fb73f4467fa248768ea1bf41c3
Autor:
E. I. Kovalenko, E. V. Artamonova, L. V. Bolotina, L. A. Zhiliaeva, D. M. Ponomarenko, E. V. Karabina, G. Z. Mukhametshina, A. I. Khasanova, E. Yu. Ratner, A. R. Safarova, A. G. Manikhas, N. O. Popova, I. V. Evstigneeva, L. Yu. Vladimirova, L. V. Kramskaya, T. V. Karandeeva, I. R. Suslova, O. V. Romanchuk, V. E. Shikina, A. Yu. Povyshev, M. A. Osipov, E. M. Cherniakova, A. S. Dergunov, M. V. Volkonskiy, I. S. Chernov, I. E. Shumskaya, M. M. Fael, V. I. Garifullina, I. E. Gudkova
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 36-46 (2021)
Introduction. The standard of 1st line treatment of HER2+ metastatic breast cancer (mBC) is double blockade with trastuzumab and pertuzumab + taxane, 2nd line – Trastuzumab-emtazine. There are no standards for further treatment, as well as the opti
Externí odkaz:
https://doaj.org/article/ddfb182fcf6247f0b4a7bd188e53d850